I have no respect for a company who tries to pass off botched trials as valid. Sure the market cap is tiny, what happens if they don't produce anything of value soon? In comes the reverse split.
I also did not like how they portrayed the old linjeta/viaject either...they compared to regular insulin instead of fast acting stuff out there and the thing was still weak. Management is shady IMHO.
I have not looked at them hard since the CRL but did see when the ph1 trial failed.
Market Data 
Markets 
AI
